Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
On a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:
Director |
For |
% |
Withheld |
% |
|
9,241,477 |
84.78 % |
1,659,014 |
15.22 % |
|
8,154,250 |
74.81 % |
2,746,241 |
25.19 % |
Matth ew C. Coffey |
7,736,218 |
70.97 % |
3,164,273 |
29.03 % |
|
8,451,056 |
77.53 % |
2,449,435 |
22.47 % |
|
8,154,164 |
74.81 % |
2,746,327 |
25.19 % |
|
7,944,430 |
72.88 % |
2,956,061 |
27.12 % |
|
8,372,251 |
76.81 % |
2,528,240 |
23.19 % |
|
8,883,087 |
81.49 % |
2,017,404 |
18.51 % |
In addition to the election of all nominees listed as directors in the management information circular, dated
For more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at www.sedar.com. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.
About
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact |
|
Investor Relations for Oncolytics |
|
|
|
Director of IR & Communication |
|
|
|
+1-917-679-9282 |
|
|
|
Logo: https://mma.prnewswire.com/media/1762876/Oncolytics_Biotech_New_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-302147378.html
SOURCE Oncolytics Biotech® Inc.